Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

248
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
248
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

310
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
310
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

262
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
262
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

277
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
277
Liver Physiology01:30

Liver Physiology

4.1K
The liver, an essential organ in the human body, performs over 200 vital functions that can be broadly categorized into metabolic, hematological, endocrine regulation, and bile production.
Metabolic Regulation:
The liver is the central organ involved in regulating blood composition. It stabilizes blood glucose levels, maintaining them within the range of  70–110 mg/dL. When these levels drop, the liver breaks down glycogen reserves and releases glucose into the bloodstream. It can...
4.1K
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

343
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
343

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Persistent CRP Elevation at 4 Weeks Is Associated with Delayed Union After Polytrauma: An Exploratory Retrospective Cohort Study.

Diagnostics (Basel, Switzerland)·2026
Same author

Predictors of In-Hospital Mortality in Traumatic Acute Subdural Hematoma: The Role of Admission International Normalized Ratio, Imaging Parameters and Neurological Severity.

Biomedicines·2026
Same author

Asymptomatic Nasal Carriage of MRSA Among Romanian Medical Students: Prevalence and Sampling Technique Comparison.

Microorganisms·2026
Same author

Inflammatory and Endothelial Dysfunction Biomarkers Predict Severe COVID-19 in Hospitalized Patients: Development of the CCBR Model.

Biomedicines·2026
Same author

Comparison of NLR and CRP in Identifying Organ Dysfunction-Based Severe Presentation of Acute Cholangitis in Patients with Choledocholithiasis: A Single-Center Retrospective Study.

Medicina (Kaunas, Lithuania)·2026
Same author

Mast Cells Are a Reservoir of NLRP1 in Human Skin.

International journal of molecular sciences·2026

Related Experiment Video

Updated: Mar 14, 2026

The Murine Choline-Deficient, Ethionine-Supplemented CDE Diet Model of Chronic Liver Injury
07:27

The Murine Choline-Deficient, Ethionine-Supplemented CDE Diet Model of Chronic Liver Injury

Published on: October 21, 2017

12.5K

Body Composition Changes in Patients with Chronic Hepatitis C.

Ecaterina Constanța Barbu1, Cristina Emilia Chiţu-Tișu2, Mihai Lazăr3

  • 1Carol Davila University of Medicine and Pharmacy Bucharest;Dr. I. Cantacuzino Clinical Hospital, Bucharest; Prof. Dr. Matei Balş National Institute for Infectious Diseases, Bucharest, Romania. katybarbu@yahoo.com.

Journal of Gastrointestinal and Liver Diseases : JGLD
|October 1, 2016
PubMed
Summary

Chronic hepatitis C (CHC) patients exhibit reduced body fat and bone density compared to controls. Factors like low BMI, smoking, and specific treatments are linked to these body composition changes.

More Related Videos

Analysis of Liver Microenvironment During Early Progression of Non-Alcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma in Zebrafish
09:27

Analysis of Liver Microenvironment During Early Progression of Non-Alcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma in Zebrafish

Published on: April 1, 2021

4.1K
Mass Cytometry Analysis of Systemic and Local Immune Responses in Hepatocellular Carcinoma
08:25

Mass Cytometry Analysis of Systemic and Local Immune Responses in Hepatocellular Carcinoma

Published on: April 25, 2025

903

Related Experiment Videos

Last Updated: Mar 14, 2026

The Murine Choline-Deficient, Ethionine-Supplemented CDE Diet Model of Chronic Liver Injury
07:27

The Murine Choline-Deficient, Ethionine-Supplemented CDE Diet Model of Chronic Liver Injury

Published on: October 21, 2017

12.5K
Analysis of Liver Microenvironment During Early Progression of Non-Alcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma in Zebrafish
09:27

Analysis of Liver Microenvironment During Early Progression of Non-Alcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma in Zebrafish

Published on: April 1, 2021

4.1K
Mass Cytometry Analysis of Systemic and Local Immune Responses in Hepatocellular Carcinoma
08:25

Mass Cytometry Analysis of Systemic and Local Immune Responses in Hepatocellular Carcinoma

Published on: April 25, 2025

903

Area of Science:

  • Hepatology
  • Body Composition Analysis
  • Metabolic Disorders

Background:

  • Chronic hepatitis C (CHC) is a significant global health concern.
  • Body composition alterations are increasingly recognized in chronic diseases.
  • Limited research exists on soft tissue body composition changes in CHC patients compared to healthy individuals.

Purpose of the Study:

  • To quantify global and regional body composition differences in CHC patients versus controls.
  • To identify associations between body composition changes and CHC.
  • To investigate the impact of CHC on soft tissue and bone parameters.

Main Methods:

  • Dual-energy X-ray absorptiometry (DXA) was used to assess 60 CHC patients and 60 healthy controls.
  • Statistical analysis included Mann-Whitney tests for group comparisons and Spearman's rank correlation for variable associations.
  • Correlations were examined with factors including BMI, smoking, fibrosis grade, and treatment regimens.

Main Results:

  • CHC patients showed significantly lower total fat mass, trunk fat mass, and percent body fat than controls.
  • Reduced fat mass was associated with lower BMI, cigarette smoking, and peginterferon alpha 2a plus ribavirin treatment.
  • Bone mineral density (BMD) was lower in CHC patients, correlating with low BMI, smoking, and the same treatment regimen.

Conclusions:

  • CHC patients present with an acquired lipodystrophy, particularly affecting the trunk.
  • Reduced bone mineral density is also observed in CHC patients compared to controls.
  • Low BMI, smoking, and peginterferon alpha 2a/ribavirin therapy are linked to diminished fat mass and BMD in CHC.